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Abstract
Objective: To signal key issues for harmonising approaches for establishing
micronutrient recommendations by explaining observed variation in recom-
mended intakes of folate, vitamin B12, Fe and Zn for adults and elderly people.
Design: We explored differences in recommended intakes of folate, vitamin B12,
Fe and Zn for adults between nine reports on micronutrient recommendations.
Approaches used for setting recommendations were compared as well as emi-
nence-based decisions regarding the selection of health indicators indicating
adequacy of intakes and the consulted evidence base.
Results: In nearly all reports, recommendations were based on the average
nutrient requirement. Variation in recommended folate intakes (200–400mg/d)
was related to differences in the consulted evidence base, whereas variation in
vitamin B12 recommendations (1?4–3?0mg/d) was due to the selection of different
CV (10–20%) and health indicators (maintenance of haematological status or
basal losses). Variation in recommended Fe intakes (men 8–10 mg/d, pre-
menopausal women 14?8–19?6 mg/d, postmenopausal women 7?5–10?0 mg/d)
was explained by different assumed reference weights and bioavailability factors
(10–18%). Variation in Zn recommendations (men 7–14 mg/d, women
4?9–9?0 mg/d) was also explained by different bioavailability factors (24–48 %) as
well as differences in the consulted evidence base.
Conclusions: For the harmonisation of approaches for setting recommended
intakes of folate, vitamin B12, Fe and Zn across European countries, standardised
methods are needed to (i) select health indicators and define adequate biomarker
concentrations, (ii) make assumptions about inter-individual variation in
requirements, (iii) derive bioavailability factors and (iv) collate, select, interpret
and integrate evidence on requirements.
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Adequate nutrient intakes are critical to health maintenance
and contribute to the prevention of chronic diseases and
functional decline(1–13). Many countries and organisations
across Europe provide micronutrient recommendations that
serve as a basis for good health(14). Although different terms
are used to express such recommendations, e.g. Population
Reference Intakes, Recommended Intake, Recommended
Daily Allowance, they all refer to the daily intake level that
is sufficient to fulfil the requirements of nearly all healthy
individuals in a defined population(14,15).
There are two main approaches for establishing
micronutrient recommendations: the requirement-based
approach and the intake-based approach. The first approach
evaluates evidence across intervention and observational
studies on the relationship between intake and selected
health indicators. These health indicators indicate the ade-
quacy of intake to fulfil physiological needs and may include
physiological, biochemical and functional measures, equili-
brium maintenance and disease incidence(16). Based on the
distribution of nutrient requirements both the Average
Nutrient Requirement (ANR), also referred to as the Average
Requirement or Estimated Average Requirement, and the
Recommended Intake can be derived (ANR12SD).
The intake-based approach is used when evidence
needed to estimate the distribution of nutrient require-
ments is lacking or incomplete. Consequently, recom-
mendations are based on the lowest level of intake
estimated to be sufficient for nearly all healthy people within
the population, also referred to as Adequate Intake (AI).
Micronutrient recommendations serve as an important
basis for public health nutrition policy. If the distribution
of requirements can be estimated, the ANR can be used to
assess the prevalence of adequate intakes within a popu-
lation. Furthermore, if the prevalence of adequate intakes is
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not satisfactory, recommended intakes can be used for
planning interventions to improve the situation(17–19).
Currently, there is considerable variation in micro-
nutrient recommendations between countries and this
can cause confusion among policy makers, consumers,
the food industry and health professionals(14,20–22). This
variation may be due to differences between populations,
e.g. in bioavailability from national diets, but it may also
be due to differences in approaches used for establishing
recommendations (ANR1 2SD v. AI)(23) and eminence-
based decisions regarding the selection of relevant health
indicators and data underlying recommendations(16,19,23,24).
Harmonisation of the process for establishing micronutrient
recommendations will increase transparency, objectivity
and reliability of recommendations and contribute to
aligned nutrition policy across Europe(19,23).
The present paper aims to contribute to the under-
standing of the variation in recommendations and to
signal key issues for harmonising approaches for estab-
lishing recommended intakes for adults and elderly
people of four micronutrients (folate, vitamin B12, Fe and
Zn) that were prioritised by the Network of Excellence
EURRECA(25–27). First we explored differences in current
recommendations between reports from key European and
non-European countries/organisations. Second we exam-
ined whether the approaches used and the eminence-
based decisions made for establishing recommendations
contribute to the observed variation.
Methods
Collection and comparison of recommended
micronutrient intakes
By the end of 2007, and early 2008, the latest reports on
micronutrient recommendations were collected from
thirty-one European countries and organisations in col-
laboration with local key informants involved in setting
these recommendations, as described elsewhere(14).
Eight European countries, clusters of countries or
organisations provided reports on micronutrient recom-
mendations based on a review of the available literature
on nutrient requirements(14): United Kingdom (GB)(28),
Netherlands (NL)(29,30), France (FR)(31), Latvia(32), Germany–
Austria–Switzerland (DACH)(33), Norway–Sweden–Finland–
Denmark–Iceland (NNR)(34), European Community (EC)(35)
and WHO/FAO(36). The latter two defined recommenda-
tions to be used in an international perspective. Seven of
these reports were included in the present study: the Latvian
report was excluded because no information was available
on the approaches and eminence-based decisions under-
lying recommendations.
In other European countries, micronutrient recom-
mendations were adopted from at least one of the reports
mentioned above or from guidance provided in the USA/
Canada(14,37,38). Therefore, we also included the report of
USA/Canada (US/CA) in the present study. In addition the
report of Australia/New Zealand (AU/NZ)(39) was inclu-
ded, because it includes an extensive evaluation of the
recommendations previously published in USA/Canada
and considers the literature up to 2003.
From the nine reports, we extracted recommended
intakes of folate, vitamin B12, Fe and Zn for adults and
elderly people (age $18 years). To quantify the extent of
heterogeneity between reports the ratio of the highest to
the lowest recommendation observed per gender was
calculated. Within-report comparisons were used to
identify differences between men and women and
between younger and older adults.
Collection and comparison of approaches
From each report we retrieved information on the
approach used for establishing the recommendations of
interest (ANR1 2SD, or AI). If an ANR1 2SD was reported,
we obtained the ANR and inter-individual variation
coefficient (CV51003 SD/ANR). In case the ANR or CV was
not explicitly reported, the missing value was calculated
based on the following equation: ANR1 2SD5ANR3
(11 23CV/100). We evaluated whether variation in
ANR1 2SD was more strongly related to between-report
differences in ANR or CV. For each combination of two
reports with a different ANR1 2SD, we checked in what
way applying the same CV would change the difference
between the recommendations.
Collection and comparison of eminence-based
decisions
In general there are two ways to establish an ANR: (i) based
on intake–health associations or (ii) based on physiological
needs estimated by basal losses (i.e. factorial approach).
If intake–health associations are used, the ANR is estimated
by the mean intake needed to reach a specified cut-off level
of the selected health indicator. The factorial approach
includes the summation of basal losses via skin, faeces,
urine and additional needs for accretion. By correcting total
needs for bioavailability from the usual diet, the ANR
is estimated (ANR5mean physiological needs3100/
bioavailability factor). To explain potential variation in ANR
between reports we collected and compared health indi-
cators and cut-off levels or basal losses and bioavailability
factors depending on the method used to establish the ANR.
Finally, to assess the data underlying recommendations
the references that were given greatest weight by the
authors of the reports were compared between reports
that used similar methods for deriving an ANR or AI.
Results
Recommended intakes of folate, vitamin B12, Fe and
Zn for adults ($18 years) from European countries,
US/CA and AU/NZ are presented in Tables 1 and 2.
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Table 1 Recommended intakes of folate and vitamin B12 for adults (age $18 years) and underlying approaches
Method for estimating ANR/AI
Year Recommended intake (mg)* Approach ANR (mg) CV (%) Health indicator (cut-off level)- Daily losses
Folate
GB(28) 1991 200 ANR12SD 150 15 Folate levels in liver (.3mg/g)
Erythrocyte folate (.327nmol/l)
EC(35) 1993 200 ANR12SD 140 20 Serum folate (n.a.)
Erythrocyte folate (.327nmol/l)
DACH(33) 2000 400 ANR12SD n.a. 10–15 Plasma homocysteine (n.s.)
Correct deficiency symptoms (100–200mg)
FR(31) 2001 male: 330, female: 300 AI x x Plasma homocysteine (,10mmol/l)
NL(30) 2003 300 ANR12SD 200 25 Serum folate (.10nmol/l) Compensate losses (n.a.)
Erythrocyte folate (.300nmol/l)
Plasma homocysteine (,15mmol/l)
NNR(34) 2004 300 ANR12SD 200 25 Serum folate (.6?8nmol/l)
Erythrocyte folate (.317nmol/l)
US/CA(37)-
-
1998 400 ANR12SD 320 10 Serum folate (.7nmol/l)
Erythrocyte folate (.305nmol/l)
Plasma homocysteine (,16 mmol/l)
Vitamin B12
GB(28) 1991 1?5 ANR12SD 1?25 10 Haematological status-
-
(1?0mg)
Total vitamin B12 stores (n.s.)
EC(35) 1993 1?4 ANR12SD 1?0 20 Haematological status-
-
(1?0mg)
Serum vitamin B12 (.113 pmol/l)
DACH(33) 2000 3?0 ANR12SD n.a. 10–15 Haematological status-
-
0?1 % of total stores (2–5 mg)
Plasma vitamin B12 (n.s.)
FR(31) 2001 2?4 ANR12SD 2?0 10 0?8mg
NL(30) 2003 2?8 ANR12SD 2?0 20 0?2% of liver stores (500mg)
NNR(34) 2004 2?0 ANR12SD 1?4 15 Haematological statusy (0?7mg)
Serum vitamin B12 (n.a.)
Total vitamin B12 stores (1000mg)
US/CA(37)-
-
1998 2?4 ANR12SD 2?0 10 Haematological status-
-
(1?0mg)
Serum vitamin B12 ($150 pmol/l)
ANR, Average Nutrient Requirement; AI, Adequate Intake; GB, United Kingdom; EC, European Community; DACH, Germany–Austria–Switzerland; FR, France; NL, Netherlands; NNR, Norway–Sweden–Finland–
Denmark-Iceland; US/CA, USA/Canada; n.a., not available in report; x, not available because the intake-based approach was used; n.s., not specified.
Values in italics could not be retrieved from the reports, but were calculated: CV50?53 [(recommendation/ANR) 2 1].
*Recommended folate intakes were expressed as dietary folate equivalents (DFE): 1 DFE51mg food folate50?6mg folic acid from fortified foods5 0?5mg folic acid from supplements.
-Bold text indicates the primary indicator used to estimate the ANR, whereas the text not in bold indicates a secondary health indicator.
-
-
WHO/FAO and Australia/New Zealand (AU/NZ) adopted recommendations from US/CA; therefore the reports of WHO/FAO and AU/NZ were not considered separately.
yHaematological status as measured by stable Hb, normal mean cell volume and normal reticulocyte response.
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Table 2 Recommended intakes of iron and zinc for adults (age $18 years) and underlying approaches
Method for estimating ANR/AI: daily losses
Recommended intake (mg/d) ANR (mg)/50th pct CV (%) Component losses (mg/d) Total losses (mg/d)
Year m f pre f post Approach m f pre f post m1 f Faeces Urine Sweat Menstrual m f pre f post Bioav (%)
Iron
GB(28) 1991 8?7 14?8 8?7 ANR1 2SD 6?7 11?4 6?7 15 0?76 0?1 n 0?7 0?86 1?56 0?86 15
EC(35) 1993 9?1 19?6jj 7?5 ANR1 2SD** 7 9 5?8 15** n 1?05 1?46 0?87 15
DACH(33) 2000 10 15 10 ANR1 2SD n.a. n.a. n.a. 10–15 1?0 1?5 1?0 10–15
FR(31) 2001 9 16 9 AI x x x x 0?6 0?2–0?3 0?1 0?4–0?5 0?9–1?0 1?3–1?5 0?9–1?0 10
NL(29) 1992 9- 15- 8 ANR1 2SD 8 13 7 20 0?8 0?9 1?6 0?8 12
NNR(34)] 2004 9 15z 9 ANR1 2SD** 7 9 5?8 15** n 1?05 1?46 0?87 15
WHO/FAO(36) 2004 9?1-
-
19?6-
-
7?5-
-
ANR1 2SD** 7 9 5?8 15** n 1?05 1?46 0?87 15-
-
US/CA(38)* 2001 8 18 8 ANR1 2SD 6?0 8?1 5?0 n.a.-- 0?51 1?08 1?40 0?90 18
m f D m–f m f Faeces Urine Sweat Semen m f
Zinc
GB(28) 1991 9?5 7 2?5 ANR1 2SD 7?3 5?5 15 2?2 1?6 30
EC(35) 1993 9?5 7 2?6 ANR1 2SD 7?5 5?5 15 2?2 1?6 30
DACH(33) 2000 10 7 3 ANR1 2SD n.a. n.a. 10–15 2?2 1?6 30
FR(31) 2001 9-
-
,y 7--,y 2 AI x x x n.a. n.a. 30--
NL(29) 1992 10 9 1?2 ANR1 2SD 7?6 6?8 20 0?3–0?5 0?3–0?7 0?5 0?27 1?3–1?9 1?1–1?7 25
NNR(34) 2004 9 7 0?9 ANR1 2SD 6?4 5?7 15 1?4 Urine1 sweat1 semen: m: 1?27, f: 1?0 1?4 1?0 30
WHO/FAO(36) 2004 7-
-
4?9-
-
2?2 ANR1 2SD 4?7 3?2 25 2?67 2?4 40-
-
US/CA(38) 2001 11 8 3?1 ANR1 2SD 9?4 6?8 10 m: 2?57, f: 2?3 0?63 0?54 0?10 3?84 3?3 m: 41, f: 48
AU/NZ(39) 2005 14 8 6?6 ANR1 2SD 12 6?5 10 m: 1?54, f: 1?06 0?63 0?54 0?10 2?81 1?96 m: 24, f: 31
m, males; f, females; pre, premenopausal; post, postmenopausal; pct, percentile; ANR, Average Nutrient Requirement; AI, Adequate Intake; bioav, bioavailability; GB, United Kingdom; EC, European Community, DACH,
Germany–Austria–Switzerland; FR, France; NL, Netherlands; NNR, Norway–Sweden–Finland–Denmark–Iceland; US/CA, USA/Canada; AU/NZ, Australia/New Zealand; n.a., not available in report; x, not available
because the intake-based approach was used; n, negligible.
Values in italics could not be retrieved from the reports, but were calculated: CV5 0?5 3 [(recommended intake/ANR) 2 1].
*AU/NZ adopted recommendations from US/CA; therefore the report of AU/NZ was not considered separately.
-A separate recommended Fe intake was provided for men and women aged 19–21 years, m: 11?0 mg, f: 16?0 mg.
-
-
Recommended intakes of Fe and Zn were also available for other bioavailability coefficients (WHO/FAO: 5, 10 and 12 % for Fe, 15 and 50 % for Zn, FR: 20 % for Zn).
yFor men and women aged $75 years, the recommended Zn intake was 8?0 mg.
jjEC also presents the 90th percentile of intakes to fulfil physiological requirements, 15?8 mg.
zThe recommended Fe intake was set at the 90th percentile of Fe requirements.
**Not applicable for premenopausal women: the distribution of requirements was skewed and recommended Fe intake could therefore not be derived as ANR1 2SD.
--Distribution of Fe requirements for both men and women was based on the median and variability in body weights recorded in the third National Health and Nutrition Examination Survey.
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Since recommendations were similar across adult ages,
for each report we only present one recommendation per
gender. Due to the diminished Fe needs after onset of
menopause, all reports provided recommended Fe
intakes for pre- and postmenopausal women separately.
WHO/FAO and FR provided recommended intakes of
Fe and Zn for different bioavailability factors. In our
comparison, we included the recommendations esti-
mated with the bioavailability factor most frequently used
in the other reports (Fe 15 %, Zn 30 %).
Variation in recommendations
Between-report ratios of highest to lowest recommenda-
tions were about 2?0 for folate (200–400mg), vitamin B12
(1?3–3?0mg) and Zn (men 7–14 mg, women 4?9–9?0 mg),
whereas for Fe the variation was less with a ratio of about
1?3 (men 8–10 mg, premenopausal women 14?8–19?6 mg,
postmenopausal women 7?5–9?0 mg).
Within reports, we observed no gender differences for
folate and vitamin B12; only FR recommended a higher
folate intake for men (130mg). For Fe, higher recom-
mendations were established for premenopausal compared
with postmenopausal women (13mg to 112mg), whereas
recommendations for men and postmenopausal women
were similar or slightly different (EC, NL, WHO/FAO; max-
imum difference 1?6mg). For Zn all reports provided higher
recommendations for men than for women (11 to 16mg).
In general few differences existed between recom-
mendations for younger and older adults, due to limited
knowledge of the effects of the ageing process on utili-
sation and absorption of folate, vitamin B12, Fe and Zn.
However, all reports, except the one from GB, indicated
that consumption of vitamin B12 via fortified foods or
supplements is recommended for elderly people suffer-
ing from food-bound malabsorption. Due to the high
prevalence of atrophic gastritis among elderly people
(10–30 %), US/CA applied this recommendation for all
those aged 51 years and older.
Both for folate and vitamin B12 we observed a clear
difference in recommended intakes between reports of
GB and EC published until 1993 (folate 200mg, vitamin
B12 1?4–1?5mg) and the other reports published since
1998 (folate 300–400mg, vitamin B12 2?0–3?0mg).
Variation in approaches
In general, reports suggested that recommendations were
established using the requirements-based approach
(ANR1 2SD); only FR indicated providing an AI for folate,
Fe and Zn (Tables 1 and 2).
To derive recommended Fe intakes for premenopausal
women, five reports (EC, NNR, WHO/FAO, US/CA, GB)
used an alternative approach since the distribution of
menstrual Fe losses was found to be skewed. EC, NNR,
WHO/FAO and US/CA estimated the distribution of Fe
requirements for this population group as the convolution
of the distributions of menstrual and basal Fe losses and
subsequently derived recommended Fe intakes as the
90th (EC, NNR), 95th (EC, WHO/FAO) or 97?5th (US/CA)
percentile of Fe requirements. EC and NNR argued that
considering a usual diet, Fe intake fulfilling requirements of
95% of the population would be unrealistically high for the
majority of premenopausal women. GB derived an ANR for
Fe as the sum of mean basal losses and the 75th percentile
of menstrual Fe losses corrected for the bioavailability factor.
The ANR12SD was estimated by applying a CV of 15%.
Between reports CV varied from 10 to 20 % (vitamin B12
and Fe) or 10 to 25 % (folate and Zn). Part of the observed
between-report differences in ANR12SD can be explained
by variation in CV. In general for folate, Zn and Fe,
between-report differences in ANR contributed more to
the variation in recommendations than differences in CV,
as between-report differences in ANR12SD stayed similar,
decreased only slightly or even increased after applying
the same CV (data not shown). The variation in CV only
fully explained the differences in ANR12SD for vitamin B12
established by FR, NL and US/CA, and differences in
ANR12SD for Zn established by NL and US/CA. In these
cases, ANR were the same in all specified reports and
only CV varied. For Zn, some variation in ANR12SD was
more strongly related to between-report differences in CV
than in ANR both for men (GB–NL, EC–NL) and women
(NL–AU/NZ).
Variation in eminence-based decisions
For folate and vitamin B12, the maintenance of blood or
tissue levels at a concentration not accompanied by
deficiency symptoms was generally considered as health
indicator for establishing an ANR (Table 1). For folate all
countries/organisations used at least one biomarker of
folate status as primary health indicator for establishing
an ANR. Cut-off levels indicating adequate concentrations
of biomarkers showed some variation between reports:
erythrocyte folate .300–340 nmol/l, serum folate
.6?8–10?0 nmol/l, serum homocysteine ,10–16mmol/l.
EC, NL, NNR and US/CA all used adequate serum and
erythrocyte folate as health indicators, but ANR varied
from 140 to 320mg. All four reports referred to the same
depletion–repletion study by Sauberlich et al.(40). In
addition, EC based their ANR on two older depletion–
repletion studies(41,42), and NL, NNR and US/CA on a more
recent depletion–repletion study(43) and a balance study(44).
NL and US/CA also considered the randomised controlled
trial by O’Keefe et al.(45). However, NL did not use the latter
study for estimating the ANR because requirements based
on the results of that study were much higher than those in
other studies. In contrast, in the report of US/CA the
O’Keefe study was given greatest weight, as subjects in the
other depletion–repletion studies would have received
more folate than reported due to underestimation of the
folate content in food.
GB based recommended folate intakes on observa-
tional data on the relationship between long-term folate
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intake and adequate concentrations of folate in liver and
erythrocytes(43).
An optimal concentration of homocysteine was selec-
ted as health indicator for folate in reports of FR(46) and
DACH(47,48), which was explained as the level at which
the risk for CVD is minimised. On the contrary, NL, NNR
and US/CA reported that available evidence on minimis-
ing CVD risk by lowering homocysteine concentrations is
not strong enough to take this biomarker into account for
estimating folate requirements.
For vitamin B12, GB, EC, NNR and US/CA selected the
maintenance of adequate haematological status as pri-
mary health indicator for estimating the ANR (1?0–2?0mg).
EC, NNR and US/CA mainly based the ANR of vitamin B12
on Darby et al.(49), studying the effects of various intra-
muscular doses of vitamin B12 on subjects with pernicious
anaemia. NNR and US/CA corrected these levels for
reabsorption of biliary vitamin B12 as occurs in healthy
people(50–52). EC did not perform these corrections, but
assumed that adjustments for reabsorption will cancel out
adjustments needed for incomplete absorption from the
diet. Studies in vegetarians were used as supportive
data(53). In GB (ANR: 1?25mg) studies given largest weight
were different(53–57).
FR and NL estimated the ANR for vitamin B12 following
the factorial approach using estimates of basal losses
(0?8–1?0mg) and a bioavailability of 40 and 50%, respec-
tively. Estimations of basal losses were based on different
studies (FR(51,58), NL(50,52)), but ANR were similar (2?0mg).
The DACH report mentioned several health indicators,
but from the information provided we could not deduce
which indicator and data were used to estimate an ANR.
For Fe and Zn all reports used the factorial approach to
estimate the ANR (Table 2).
For Fe, the maximum difference between reports in
basal losses was 0?3 mg (premenopausal women DACH v.
NL). All reports, except GB and NL, stated that basal Fe
losses were based on physiological needs per kilogram of
body weight, namely 14mg/kg per d. Reference body
weights selected for estimating an ANR varied between
reports (men 74?0–77?4 kg, women 59–64 kg). Using the
highest or lowest observed reference weight would result
in a difference in ANR of #1?2 mg.
In most countries/organisations, basal Fe losses were
based on a single experimental study by Green et al.(59)
using radio-labelled Fe to measure losses from different
body compartments. US/CA reported that Green’s was
the only study with reliable quantitative data for basal Fe
losses in human subjects. A previous report on recom-
mendations published by FAO(60) was also indicated
three times as an important reference.
In contrast, FR, DACH and NL did not refer to the
experimental study by Green et al.(59): FR referred to the
FAO report(60), NL used data from other balance, turnover
and depletion–repletion studies(61–63) and DACH did not
provide information on their evidence base.
For estimates of menstrual Fe losses, all reports, except
FR and NL, referred to the same study from year 1966(64).
Although the evidence base used in FR and NL was
different, their estimated basal losses were similar to
estimates provided in the other reports.
Bioavailability factors for Fe varied between reports
from 5 to 18 %. They were mainly based on studies
investigating bioavailability from diets with ratios of haem
Fe to non-haem Fe representative of national (NL, FR,
NNR, US/CA) or Western/mixed diets (GB, DACH, WHO/
FAO, EC) in Fe-replete subjects with minimal or normal
Fe stores. FR applied a bioavailability factor of 10 %, but
indicated that in subjects without Fe stores bioavailability
could reach 15–20 %, whereas US/CA estimated an ANR
for those with normal Fe status but minimal stores and
applied a factor of 18 %.
For Zn, total losses varied substantially (men:
1?3–3?8 mg; women: 1?0–3?3 mg); on intestinal losses in
particular there was no agreement (men: 0?3–2?57mg;
women: 0?3–2?3mg). All countries/organisations used dif-
ferent combinations of studies to estimate the ANR, but all
except FR and NNR refer to the balance study by Milne
et al.(65). Other important sources of evidence reported in at
least three reports were a depletion–repletion study(66) (NL,
NNR, WHO/FAO), the study by Hess et al.(67) measuring Zn
excretion in young women on low Zn intakes (NNR, WHO/
FAO, US/CA, AU/NZ), a book chapter(68) (GB, EC, DACH)
and a cohort study(69) (WHO/FAO, US/CA, AU/NZ).
Bioavailability factors for Zn varied between reports
from 15 to 50 %. US/CA and AU/NZ applied higher
bioavailability factors for women than for men, which
contributed to observed gender differences in ANR
(respectively 2?6 mg and 5?5 mg). More recent reports
(NNR, US/CA, AU/NZ) based bioavailability factors on the
relationship between the amount of Zn absorbed and that
excreted via the intestine based on mixed diets. AU/NZ
estimated their factor with results from the International
Zinc Nutrition Consultative Group(70), which was lower than
factors provided by NNR and US/CA (40–48%). The other
reports based bioavailability factors on studies investigating
absorption efficiency from different types of diets. Although
the evidence base varied between reports bioavailability
factors in these reports were similar (25–30%).
Discussion
Based on our comparisons of approaches and eminence-
based decisions underlying the establishment of recom-
mended intakes of folate, vitamin B12, Fe and Zn, we
identified explanations for the variation in current
recommendations. For folate selected health indicators
were similar between reports and the variation was
mainly related to differences in the underlying data. In
contrast, for vitamin B12 variation in CV and selected
health indicators (maintenance of haematological status
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or basal losses) seemed to contribute most to the
observed variation. For Fe, differences in reference
weights and bioavailability factors were the main expla-
natory factors for the variation in recommendations as the
underlying data and consequently the estimates of basal
losses were similar in most reports. For Zn the variation
in recommended intakes was related to differences in
CV, bioavailability factors and the large variation in the
evidence base.
Although the reports that we considered were pub-
lished over 13–14 years, access to new data and changes
in concepts of nutrition did not seem to have altered the
estimates made by the newer panels, except for folate.
Recommended folate intakes published until year 1993
(GB and EC) were based on older studies as compared
with the other reports published since 1998.
The present paper describes the situation at the
beginning of 2008. Since then several countries have pub-
lished updates for one or more micronutrients. However, for
the countries/organisations, micronutrients and age groups
included in the comparison herein, no updates were iden-
tified. All most recent recommendations and ANR provided
by European countries and organisations are collated in
EURRECA’s web-based tool Nutri-RecQuest(71).
In general, the requirements-based approach was used
to establish recommendations. Only FR indicated providing
an AI for folate, Fe and Zn, although the type of health
indicators and data selected as the basis for recommenda-
tions were similar to other reports providing an ANR12SD.
Apparently there is no consensus on the use of this term.
In 2007, a working group of international experts
reviewed the harmonisation of approaches for develop-
ing recommendations on nutrient intakes. They proposed
new terminology and developed a new statistical
approach for establishing recommendations. With this
new approach, recommendations do not necessarily
reflect ANR12SD covering the needs of 97?5% of the
population, but lower levels in the distribution of require-
ments may also be chosen when this is more likely to be
achieved with current nutrition policies(23). Clearly, estimates
of inter-individual variation depend on the health indicator
selected to be most reflective of meeting nutritional needs.
However, for folate, vitamin B12 and Zn, CV varied largely
between reports using the same health indicators, as data on
inter-individual variation in requirements are unavailable,
inadequate or inconsistent and therefore assumptions are
made based on variation in metabolic rates, variation in
bioavailability and/or the level of uncertainty in the ANR
estimate. More research is needed to define CV, but as long
as appropriate data are lacking, international consensus on
how to make assumptions regarding inter-individual varia-
tion in requirements of folate, vitamin B12 and Zn will help to
harmonise approaches for setting recommendations.
Health indicators selected for estimating requirements
for folate, vitamin B12, Fe and Zn varied between reports
and included biomarker concentrations rather than
associations between intake and health outcomes such as
organ function or chronic disease risk. Cut-off levels
indicating adequate concentrations of biomarkers were
based on the prevention of deficiency symptoms,
whereas their predictive value for health outcomes was
not often considered. Moreover, along with the observa-
tion that similarities in the consulted evidence base often
lead to different ANR of folate and vitamin B12, the
example on optimal concentrations of homocysteine for
the prevention of CVD illustrates that methods used for
the selection, evaluation and integration of data were not
consistent between reports. The Institute of Medicine
developed an analytical framework for setting nutrient
reference values for optimal health based on associations
between dietary exposure (intake) and clinical health
outcomes (chronic diseases)(72). The use of standard
systematic review methodology including meta-analyses
for evaluating data on these associations will contribute to
increased transparency of the decision-making process
and could therefore be an important step in harmonising
approaches for setting micronutrient recommenda-
tions(72,73). However, the use of chronic disease outcomes
for setting recommended micronutrient intakes may be
challenging due to the lack of data on associations
between intake and such clinical outcomes and due to the
multifactorial nature of chronic diseases including factors
such as genetics, age, diet, environment and lifestyle(73).
In addition, it could be questioned whether establishing
an ANR based on associations between intake and
chronic disease risk would be possible as it seems very
challenging to estimate the intake at which 50 % of the
population is at risk and 50% is not. Setting an AI seems
more feasible as it represents the intake level that resulted
in the greatest reduction of risk of disease(72,74). As data
on direct associations between intake and clinical out-
comes are often lacking, biomarkers that correlate both
with intake and a disease or physiological state may be
used as an intermediary between intake and health(72,73).
Recently, within the scope of the EURRECA Network of
Excellence, best practice methods for assessing
intake(75,76) and best practice biomarkers have been
evaluated for all nutrients of interest(11,77–79) by means of
standardised systematic review methodology(80). Up to
now, these best practice biomarkers have not yet been used
for estimating requirements, except for folate (erythrocyte
folate and serum/plasma folate). Currently within EURRECA,
systematic reviews including meta-analyses are carried out
to evaluate the strength and quality of dose–response rela-
tionships between intake and status of the priority micro-
nutrients and between micronutrient intake or status and
various health outcomes. Following standardised protocols,
these reviews will make transparent what evidence is
available addressing populations and outcomes of interest
and they may enhance the selection of health indicators(73).
Dose–response relationships for Fe and Zn might be
especially difficult to estimate due to a lack of sensitive
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and specific biomarkers reflecting status and due to the
strong homeostatic regulation of body Fe and Zn(81). The
factorial approach may therefore be the most appropriate
way of estimating ANR on both minerals assuming
a certain level of bioavailability. Bioavailability of Fe and
Zn is influenced by the composition of the diet as well
as individual characteristics including micronutrient sta-
tus, age, genotype and clinical conditions influencing
absorption and utilisation(81–83). Absorption of Fe depends
on the form of Fe (haem or non-haem) and the presence of
factors enhancing or inhibiting absorption like vitamin C
and phytate(81,84). In addition, homeostatic adaptations
occur, increasing or decreasing fractional absorption when
intake or status is low or high(81). For Zn, bioavailability is
also influenced by factors enhancing or inhibiting absorp-
tion, by individual Zn intake and status, and it may also be
influenced by ageing(85). Variation in bioavailability factors
between reports was related both to differences in diet
composition between countries and differences in meth-
odologies for deriving bioavailability factors. To align
methods of deriving bioavailability factors for Fe and Zn,
agreement is needed on how to estimate the effects of
meal composition and individual characteristics such as
micronutrient status, genetic variation (single nucleotide
polymorphisms) and age on bioavailability(83,86,87).
In conclusion, for the harmonisation of approaches for
setting recommended intakes of folate, vitamin B12, Fe
and Zn across European countries, standardised methods
are needed to: (i) select health indicators and define
adequate biomarker concentrations; (ii) make assump-
tions about inter-individual variation in requirements;
(iii) derive bioavailability factors; and (iv) collate, select,
interpret and integrate evidence on requirements.
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